Americas And Europe Chagas Disease Drugs Market By Drug Type (Benznidazole, Nifurtimox ) - Growth, Future Prospects & Competitive Analysis, 2017 – 2025

Chagas disease, or American trypanosomiasis, is an inflammatory disease caused by the protozoan parasite Trypanosoma cruzi. It is characterized by inflammation of tissue, most of the heart and intestinal tract. According to the World Health Organization (WHO), about 8 million people are infected with Chagas disease around the globe, predominantly in Latin America. WHO and the Center for Disease Control and Prevention (CDC) consider Chagas disease a neglected tropical disease. The rising number of travelers and migrants from Latin America to other countries is the prime factor driving the growth of the Chagas disease drug market in non-endemic countries. Increased urbanization in Latin America and population migration from endemic regions have led to the Chagas disease being increasingly diagnosed in non-endemic regions. Because of the high number of Latin American immigrants, Spain has the highest number of people infected with Chagas disease among European countries.

The report titled "Chagas Disease Drugs Market: Growth, Future Prospects, and Competitive Analysis, 2017–2025" covered in-depth information related to the Chagas disease drug market, accompanied by market size estimates for the duration of 2015–2025. The research study provides detailed information related to market segments, including drug type and geography. Based on the drug class, the global Chagas disease drug market is categorized into benznidazole, Nifurtimox, and others. Although there is no vaccine available for the treatment of Chagas disease, anti-parasitic drugs such as Benznidazole and Nifurtimox are effective.

For the purpose of the study, the global Chagas disease drugs market is regionally categorized as North America (United States and Canada), Latin America (Argentina, Brazil, Mexico, and the Rest of Latin America), and Europe (Spain, France, the United Kingdom, and the Rest of Europe) because affected populations mostly exist in these regions.

Quantitative and qualitative information is included in the report for an in-depth analysis of the current market scenario and future prospects. The report also includes factors such as drivers, opportunities, and challenges to help readers better understand current market trends.

The Chagas disease drugs market in America and Europe is divided into the following segments based on drug type:

  • Benznidazole
  • Nifurtimox
  • Other

Currently, there is no vaccine available for the treatment of Chagas disease; however, a few parasitic drugs are used in treatment. Benznidazole and Nifurtimox have both been shown to be effective in the treatment of Chagas disease. These drugs can completely cure the disease if administered at an earlier stage. Benznidazole and Nifurtimox are included in the World Health Organization's (WHO) list of essential medicines for children. In recent years, benznidazole has been the major revenue-generating segment, as the drug is used as a first-line treatment option due to its safety and efficacy. Benznidazole is the first approved drug in the United States for the treatment of Chagas disease. Previously, benznidazole was available in the United States through a special program run by the CDC. In August 2017, the FDA approved benznidazole by using the accelerated approval pathway and granting orphan drug designation. However, problems in drug supply, drug shortages, limited accessibility, and a lack of guidelines supporting implementation are hindering the growth of the Chagas disease drug market. Nifurtimox is not yet approved by the FDA in the United States, but it can be accessed via the CDC under an expanded access protocol. Other drugs, such as angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, adrenergic beta-blockers, etc., are used to reduce mortality. Pacemakers, ablations, implantable cardioverter-defibrillators, heart transplantation, and other treatments are used in patients with advanced Chagas disease.

The Chagas disease drug market in the Americas and Europe is divided into three segments for the purposes of this study:

  • North America
    • United States
    • Canada
  • Europe
    • United Kingdom
    • Spain
    • France
    • Rest of Europe
  • Latin America (LATAM)
    • Argentina
    • Brazil
    • Mexico
    • rest of Latin America

Chagas disease is one of the biggest public health issues in Latin America, causing more than 10,000 deaths each year. The highest number of people with Chagas disease exists in Argentina, Brazil, and Mexico, followed by Bolivia and Colombia. The WHO and the Center for Disease Control and Prevention (CDC) considered Chagas disease a neglected tropical disease. For the treatment of Chagas disease, benznidazole and Nifurtimox are recommended. It is estimated that the United States will show the fastest market growth during the forecast period primarily due to higher healthcare awareness among the general population and an increase in the number of migrants from endemic regions to the United States. The chagas disease largely affects people in rural parts of Latin America, but due to the growing number of people migrating from endemic countries to the United States, the number of affected people in the United States increased. According to the CDC, there are about 300,000 people infected with Chagas disease in the United States. Benznidazole was previously available through the CDC in the United States; however, due to an increase in the number of affected individuals, the FDA granted Benznidazole approval (in August 2017). Benznidazole is the first and only approved drug in the United States for Chagas disease treatment.

Frequently Asked Questions:

The market for Americas And Europe Chagas Disease Drugs is expected to reach US$ XX Mn in 2025.

The Americas And Europe Chagas Disease Drugs market is expected to see significant CAGR growth over the coming years,at 1.5%.

The report is forecasted from 2017-2025.

The base year of this report is 2016.

Bayer AG.,F. Hoffmann-La Roche Ltd.,Humanigen, Inc.,Johnson & Johnson,KaloBios Pharmaceuticals, Inc. are some of the major players in the global markHet.

Choose License Type
Trusted By
Published Date:  Nov 2017
Category:  Pharmaceuticals
Report ID:   58849
Report Format:   PDF
Pages:   120
Rating:    4.8 (70)
Delivery Time: 24 Hours to 48 Hours   
Connect With Us
24/7 Research Support